AU2008329070B2 - MCP-I binding nucleic acids and use thereof - Google Patents

MCP-I binding nucleic acids and use thereof Download PDF

Info

Publication number
AU2008329070B2
AU2008329070B2 AU2008329070A AU2008329070A AU2008329070B2 AU 2008329070 B2 AU2008329070 B2 AU 2008329070B2 AU 2008329070 A AU2008329070 A AU 2008329070A AU 2008329070 A AU2008329070 A AU 2008329070A AU 2008329070 B2 AU2008329070 B2 AU 2008329070B2
Authority
AU
Australia
Prior art keywords
nucleotide sequence
nucleic acid
stretch box
mcp
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008329070A
Other languages
English (en)
Other versions
AU2008329070A1 (en
Inventor
Klaus Buchner
Dirk Eulberg
Florian Jarosch
Sven Klussmann
Christian Maasch
Werner Purschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of AU2008329070A1 publication Critical patent/AU2008329070A1/en
Application granted granted Critical
Publication of AU2008329070B2 publication Critical patent/AU2008329070B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2008329070A 2007-11-30 2008-11-29 MCP-I binding nucleic acids and use thereof Ceased AU2008329070B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023267.3 2007-11-30
EP07023267 2007-11-30
PCT/EP2008/010167 WO2009068318A1 (en) 2007-11-30 2008-11-29 Mcp-i binding nucleic acids and use thereof

Publications (2)

Publication Number Publication Date
AU2008329070A1 AU2008329070A1 (en) 2009-06-04
AU2008329070B2 true AU2008329070B2 (en) 2014-11-20

Family

ID=40415282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008329070A Ceased AU2008329070B2 (en) 2007-11-30 2008-11-29 MCP-I binding nucleic acids and use thereof

Country Status (12)

Country Link
US (2) US20100311816A1 (enExample)
EP (1) EP2229442A1 (enExample)
JP (1) JP5777341B2 (enExample)
KR (1) KR20100092463A (enExample)
CN (1) CN101878305A (enExample)
AU (1) AU2008329070B2 (enExample)
BR (1) BRPI0819845A2 (enExample)
CA (1) CA2707089A1 (enExample)
MX (1) MX2010005916A (enExample)
RU (1) RU2542973C2 (enExample)
WO (1) WO2009068318A1 (enExample)
ZA (1) ZA201002974B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984501B1 (en) 2006-02-14 2011-05-18 Noxxon Pharma AG Mcp-i binding nucleic acids
WO2009068318A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-i binding nucleic acids and use thereof
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
CN102621331B (zh) * 2012-04-05 2014-07-30 中国医学科学院病原生物学研究所 一种检测或辅助检测结核性胸膜炎的试剂盒
WO2015062743A1 (en) * 2013-11-04 2015-05-07 Noxxon Pharma Ag Means and methods for the treatment of nephropathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093409A2 (en) * 2006-02-14 2007-08-23 Noxxon Pharma Ag Mcp-i binding nucleic acids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
DK2431377T3 (en) * 2001-10-26 2017-08-14 Noxxon Pharma Ag Modified L-nucleic acids
WO2003093472A2 (de) * 2002-05-06 2003-11-13 Grünenthal GmbH Cgrp bindende nukleinsäuren
EP1530635B1 (en) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin binding nucleic acids
AU2004231087B2 (en) * 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
WO2005084412A2 (en) * 2004-03-05 2005-09-15 Archemix Corp. Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
US20060257359A1 (en) * 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
WO2009068318A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-i binding nucleic acids and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093409A2 (en) * 2006-02-14 2007-08-23 Noxxon Pharma Ag Mcp-i binding nucleic acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERS, H.-J. et al. "Spiegelmer NOX-E36 for the treatment of chronic inflammatory diseases: A new chemical entity that inhibits CCL2/MCP-1." Naunyn-Schmiedegerg's Arch. of Pharm., 01 March 2007. vol. 375, no. Sup.1, p. 53, abstract 241 *
KULKARNI, O. et al. "Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus Nephritis in MRL-(Fas)lpr Mice" Journal of the American Society of Nephrology, August 2007. vol. 18, no. 8. *

Also Published As

Publication number Publication date
RU2010126662A (ru) 2012-01-10
US20100311816A1 (en) 2010-12-09
WO2009068318A1 (en) 2009-06-04
EP2229442A1 (en) 2010-09-22
KR20100092463A (ko) 2010-08-20
US20150141496A1 (en) 2015-05-21
AU2008329070A1 (en) 2009-06-04
CA2707089A1 (en) 2009-06-04
MX2010005916A (es) 2010-06-11
CN101878305A (zh) 2010-11-03
BRPI0819845A2 (pt) 2015-06-16
RU2542973C2 (ru) 2015-02-27
JP2011504736A (ja) 2011-02-17
JP5777341B2 (ja) 2015-09-09
ZA201002974B (en) 2011-07-27

Similar Documents

Publication Publication Date Title
US8367629B2 (en) MCP-1 binding nucleic acids and use thereof
US10273480B2 (en) MCP-1 binding nucleic acids
US20150141496A1 (en) MCP-1 Binding Nucleic Acids and Use Thereof
EP3065744B1 (en) A ccl2 antagonist for use in treating proteinuria
MX2008010489A (en) Mcp-i binding nucleic acids
HK1129127B (en) Mcp-1 binding nucleic acids
HK1145696A (en) Mcp-i binding nucleic acids and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired